ISIN | LU2226244361 |
---|---|
Valor Number | |
Bloomberg Global ID | |
Fund Name | Galileo – Biotech Innovation Fund BC USD |
Fund Provider |
IPConcept (Luxemburg) S.A.
Zürich, Switzerland Phone: +352 260248-1 E-Mail: info.lu@ipconcept.com Web: www.ipconcept.com |
Fund Provider | IPConcept (Luxemburg) S.A. |
Representative in Switzerland |
IPConcept (Schweiz) AG Zürich Phone: +41 044 224 32 09 |
Distributor(s) | Bellecapital AG |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund charges a transaction fee (contribution towards expenses incurred in the investment of new assets) |
Redemption Condition | The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel) |
Investment Strategy *** | The objective of the investment policy for the sub-fund is to achieve an appropriate level of growth in the sub-fund currency while taking the investment risk into account. The sub-fund is actively managed. The composition of the portfolio is determined by the Fund Manager solely in accordance with the criteria laid down in the investment objectives / the investment policy, is regularly reviewed and, if necessary, adjusted. The sub-fund is not managed using an index as a benchmark. |
Peculiarities |
Current Price * | 47.26 USD | 17.09.2025 |
---|---|---|
Previous Price * | 46.96 USD | 16.09.2025 |
52 Week High * | 58.72 USD | 20.09.2024 |
52 Week Low * | 33.21 USD | 09.04.2025 |
NAV * | 47.26 USD | 17.09.2025 |
Issue Price * | 47.26 USD | 17.09.2025 |
Redemption Price * | 47.26 USD | 17.09.2025 |
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 30,307,563 | |
Unit/Share Assets *** | 29,263,360 | |
Trading Information SIX |
YTD Performance | +0.62% |
30.12.2024 - 17.09.2025
30.12.2024 17.09.2025 |
---|---|---|
YTD Performance (in CHF) | -12.52% |
30.12.2024 - 17.09.2025
30.12.2024 17.09.2025 |
1 month | +1.68% |
18.08.2025 - 17.09.2025
18.08.2025 17.09.2025 |
3 months | +17.56% |
17.06.2025 - 17.09.2025
17.06.2025 17.09.2025 |
6 months | +10.91% |
17.03.2025 - 17.09.2025
17.03.2025 17.09.2025 |
1 year | -17.72% |
17.09.2024 - 17.09.2025
17.09.2024 17.09.2025 |
2 years | -9.57% |
18.09.2023 - 17.09.2025
18.09.2023 17.09.2025 |
3 years | -35.89% |
19.09.2022 - 17.09.2025
19.09.2022 17.09.2025 |
5 years | -68.49% |
31.03.2021 - 17.09.2025
31.03.2021 17.09.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Krystal Biotech Inc | 9.62% | |
---|---|---|
Arcellx Inc | 7.65% | |
Vertex Pharmaceuticals Inc | 5.20% | |
Alnylam Pharmaceuticals Inc | 4.95% | |
BioNTech SE ADR | 4.68% | |
Regeneron Pharmaceuticals Inc | 4.40% | |
Sarepta Therapeutics Inc | 3.05% | |
Stoke Therapeutics Inc | 2.88% | |
Moderna Inc | 2.82% | |
Beam Therapeutics Inc | 2.63% | |
Last data update | 28.02.2025 |
TER *** | 0.47% |
---|---|
TER date *** | 30.06.2025 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | |
Ongoing Charges *** | 0.44% |
SRRI ***
|
|
SRRI date *** | 31.08.2025 |